Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Booth

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Cancer Biology & Therapy|December 9, 2017
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinibLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Oncotarget|August 19, 2025
The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells <i>in vitro</i> and <i>in vivo</i>Laurence Booth, Michael R Booth, Jane L Roberts, et al.
Journal of Clinical & Cellular Immunology|December 14, 2016
AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded ProteinsLaurence Booth, Jane L Roberts, Heath Ecroyd, et al.
Oncotarget|March 26, 2016
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signalingLaurence Booth, Jane L Roberts, Mehrad Tavallai, et al.
Molecular Pharmacology|December 20, 2013
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cellsLaurence Booth, Jane L Roberts, Nichola Cruickshanks, et al.
Journal of Cellular Physiology|October 11, 2014
PDE5 inhibitors enhance celecoxib killing in multiple tumor typesLaurence Booth, Jane L Roberts, Nichola Cruickshanks, et al.
Journal of Cellular Physiology|December 30, 2014
GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human diseaseLaurence Booth, Jane L Roberts, Devin R Cash, et al.
Journal of Cellular Physiology|April 11, 2015
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial DiseasesJane L Roberts, Mehrad Tavallai, Aida Nourbakhsh, et al.
Oncotarget|February 18, 2016
Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone functionLaurence Booth, Brian Shuch, Thomas Albers, et al.
Autophagy|January 26, 2018
TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibitionSantiago Lima, Kazuaki Takabe, Jason Newton, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Cancer Biology & Therapy|December 9, 2017
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinibLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Oncotarget|August 19, 2025
The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells <i>in vitro</i> and <i>in vivo</i>Laurence Booth, Michael R Booth, Jane L Roberts, et al.
Journal of Clinical & Cellular Immunology|December 14, 2016
AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded ProteinsLaurence Booth, Jane L Roberts, Heath Ecroyd, et al.
Oncotarget|March 26, 2016
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signalingLaurence Booth, Jane L Roberts, Mehrad Tavallai, et al.
Molecular Pharmacology|December 20, 2013
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cellsLaurence Booth, Jane L Roberts, Nichola Cruickshanks, et al.
Journal of Cellular Physiology|October 11, 2014
PDE5 inhibitors enhance celecoxib killing in multiple tumor typesLaurence Booth, Jane L Roberts, Nichola Cruickshanks, et al.
Journal of Cellular Physiology|December 30, 2014
GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human diseaseLaurence Booth, Jane L Roberts, Devin R Cash, et al.
Journal of Cellular Physiology|April 11, 2015
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial DiseasesJane L Roberts, Mehrad Tavallai, Aida Nourbakhsh, et al.
Oncotarget|February 18, 2016
Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone functionLaurence Booth, Brian Shuch, Thomas Albers, et al.
Autophagy|January 26, 2018
TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibitionSantiago Lima, Kazuaki Takabe, Jason Newton, et al.
Pageof 10